Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited · Author: FormBlends Editorial
Key Takeaways
- Selena Gomez has consistently attributed her weight fluctuations to lupus medication, particularly corticosteroids, which cause water retention and central weight gain
- No statement, interview, or credible reporting has placed her on Ozempic or any GLP-1 medication
- The visible pattern of her body changes (cycling up and down, facial roundness during flare periods, normalization between cycles) fits corticosteroid-related fluctuation, not GLP-1 weight loss
- She received a kidney transplant in 2017 and continues to manage lupus, which means her treatment regimen is ongoing and her appearance reflects her health, not a cosmetic intervention
- Speculating about a chronic-illness patient's medication based on appearance ignores the visible signature of her actual treatment
Direct answer
No. Selena Gomez has stated her weight changes come from lupus medication, not Ozempic. The clinical pattern she displays (cycling fluctuations, facial roundness during flares, central adiposity) is consistent with corticosteroid use, which is standard in lupus and post-transplant immunosuppression. GLP-1 weight loss produces a different visible signature. There is no credible evidence she has used any GLP-1 medication.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What Selena Gomez has actually said about her body
- Her medical history in brief: lupus, transplant, and ongoing treatment
- Why corticosteroid weight change looks different from GLP-1 weight loss
- The timeline: cycling fluctuations versus medication trajectories
- How chronic illness gets misread as cosmetic intervention
- The clinical signature of GLP-1 use and why it does not fit her case
- Can lupus patients use Ozempic at all?
- The decision framework: should chronic-illness patients consider GLP-1 therapy?
- What public speculation does to chronic-illness patients
- The contrary view: could she be using something nobody knows about?
- FAQ
- Sources
What Selena Gomez has actually said about her body
Gomez has been more public about her body and her illness than most celebrities at her level of fame. The pattern across roughly a decade of statements is consistent.
In a 2020 interview with Allure, she described the cycle: "My weight fluctuates because of my medication. There’s nothing I can do about it." She framed her weight as outside her control in a way most celebrity weight discussions do not.
In a 2023 TikTok response to body-shaming comments, she addressed Ozempic speculation directly. According to widely cited coverage of the video, she said her medication "holds water weight" and that her body changes based on what her doctors prescribe at any given time. She has emphasized that this is not a vanity discussion for her, it is a chronic illness discussion.
In a 2024 conversation with Time about her mental-health platform Wondermind, she touched on the theme again: she is not in control of her body the way fans assume she is, and the assumption that her weight reflects her choices reflects a misunderstanding of what lupus treatment looks like.
No on-the-record statement has placed her on a GLP-1 medication. Her language across years has been consistent in attributing changes to her chronic-illness regimen.
Her medical history in brief: lupus, transplant, and ongoing treatment
Gomez first disclosed her lupus diagnosis publicly in 2015. The disease is a chronic autoimmune condition that can affect multiple organ systems. Her case was severe enough to require a kidney transplant in 2017, donated by her friend Francia Raisa.
A few clinical facts that matter for understanding her appearance:
- Lupus treatment commonly includes corticosteroids (prednisone is the most familiar example), which are dosed up during flares and tapered between them
- Post-transplant patients typically take long-term immunosuppression, which often includes maintenance corticosteroids in addition to drugs like tacrolimus or mycophenolate
- Both classes of medication can produce weight gain, fluid retention, central adiposity, and facial roundness
- Both can also affect mood, sleep, and energy in ways that complicate diet and activity
This treatment context produces a body that fluctuates with medication dosing, not a body that follows a steady upward or downward trajectory. That is the pattern Gomez has shown publicly over roughly a decade.
Why corticosteroid weight change looks different from GLP-1 weight loss
The two medication classes produce nearly opposite visible signatures. Understanding the difference is most of the work in evaluating speculation about her.
| Feature | Corticosteroid pattern | GLP-1 pattern |
|---|---|---|
| Direction of change | Weight gain, often rapid | Weight loss, typically gradual |
| Fluid retention | Significant; visible in face and extremities | Minimal |
| Facial appearance | Rounding, puffiness ("moon face") | Hollowing as weight drops |
| Body fat distribution | Central; trunk and abdomen affected more than limbs | Proportional reduction across body |
| Timing of change | Cycles with dosing; flares produce visible swings | Steady trajectory over months |
| Subjective experience | Hunger often increased; cravings common | Appetite suppression; reduced food noise |
| Reversal pattern | Resolves with tapering, often partially | Regain when medication stops, per STEP 1 extension |
Gomez has shown the corticosteroid pattern across multiple years: visible roundness during flare periods, normalization between them, and a body shape that responds to her treatment cycle rather than to a steady weight-loss arc.
The timeline: cycling fluctuations versus medication trajectories
A medication-driven weight-loss arc has a recognizable shape. The chronic-illness fluctuation pattern has a different one. Mapping Gomez’s public appearances against her stated treatment context shows the latter.
| Period | Public context | Appearance pattern |
|---|---|---|
| 2014-2015 | Initial lupus disclosure | Visible weight gain attributed to chemotherapy-style treatment |
| 2017 | Kidney transplant | Post-surgical changes; high-dose immunosuppression |
| 2019-2020 | Active music release period | Higher weight relative to earlier career; attributed to medication |
| 2021 | "Only Murders in the Building" debut | More slender appearance during a stable period |
| 2023 | TikTok body-shaming response | Visible roundness; attributed publicly to medication |
| 2024 | Engagement, ongoing TV work | Variable; not on a single trajectory |
The pattern is up and down across years, not down across many months. That is the lupus-treatment signature, not the GLP-1 signature.
How chronic illness gets misread as cosmetic intervention
The Gomez speculation is a useful case study in how chronic illness collides with celebrity weight discourse.
The assumption baked into most Ozempic speculation is that any visible weight change in a famous woman reflects an intentional intervention. The implicit model is that bodies are static unless someone chooses otherwise, and choices are presumed to be cosmetic.
For chronic-illness patients, the model is wrong. Bodies fluctuate based on disease activity, treatment dosing, immune response, and the side effects of medications that are not optional. The patient is not making aesthetic decisions in those moments. She is managing a disease that, in Gomez’s case, has already required a transplanted kidney.
Three patterns recur when chronic-illness bodies are read as cosmetic:
Pattern 1: Loss attributed to medication, illness attributed to lifestyle. When a chronic-illness patient loses weight during a difficult treatment phase, observers often assume Ozempic. When the same patient gains weight from steroids, observers often assume poor diet. Neither read is accurate; both reflect medication.
Pattern 2: Visible facial change interpreted out of context. Corticosteroid moon face is a recognizable clinical sign. When viewers see it without context, they may interpret it as ordinary weight gain, then interpret the post-taper reduction as Ozempic-style weight loss. The cycle is dosed medication, not GLP-1 therapy.
Pattern 3: Public statements ignored. Gomez has explained her body context repeatedly. Speculation about Ozempic continues despite consistent public attribution to lupus treatment. The pattern reflects audience preference for narrative over patient testimony.
The clinical signature of GLP-1 use and why it does not fit her case
Even setting aside her stated medical context, the positive case for GLP-1 use in Gomez is weak. Five signals point the other direction.
Signal 1: Direction of fluctuation. GLP-1 medications produce sustained downward weight movement over months, with weight stabilizing at a new lower baseline. Gomez’s pattern moves both directions across years, with no sustained downward trajectory.
Signal 2: Facial volume pattern. GLP-1 weight loss produces gradual facial hollowing proportional to total body fat loss (Rohrich et al., Plastic and Reconstructive Surgery 2022). Gomez’s facial pattern has shown rounding during identified treatment intensifications, not progressive hollowing.
Signal 3: Appetite language absent. Patients on GLP-1 medications consistently describe reduced appetite, "food noise" quieting, and early satiety. Gomez’s public conversation about food and weight does not include that language. She speaks about fluid retention and medication cycles instead, which is corticosteroid language.
Signal 4: Nausea silence. Roughly 60% of GLP-1 patients in the STEP 1 trial (Wilding et al., NEJM 2021) reported nausea, often significant. Gomez has done hundreds of public appearances. No GI complaint patterns consistent with GLP-1 initiation have been visible in that record.
Signal 5: Clinical context. She is already on multiple chronic-illness medications managed by a rheumatology and transplant team. Adding an off-label cosmetic medication without disclosure would be unusual in a patient with her treatment complexity, and her treatment team would have specific concerns to address before initiating.
Can lupus patients use Ozempic at all?
This question gets asked seriously by patients with autoimmune disease, separate from the celebrity speculation. The honest answer is: it depends, and the decision is more complicated than for a typical patient.
Considerations that matter for autoimmune patients:
- Drug interactions with immunosuppressants are not well characterized for GLP-1 medications specifically; absorption changes from delayed gastric emptying can affect serum levels of other drugs
- GI side effects (nausea, vomiting) can compound symptoms patients are already managing
- Pancreatitis, listed as a risk for GLP-1 medications, is a concern that needs careful screening in patients with complex medication regimens
- Post-transplant patients require coordination with their transplant team; the kidney function aspect of GLP-1 therapy matters, especially for patients with a single functioning kidney
- Weight management in chronic-illness patients is rarely an isolated decision; it sits inside disease-activity considerations, medication tolerance, and quality of life
None of this rules out GLP-1 use for chronic-illness patients who meet FDA criteria. It does mean the decision belongs to a coordinated care team, not a direct-to-consumer interface designed for healthier baselines.
For Gomez specifically, the public statements suggest her medication picture is shaped by lupus management. Whether a GLP-1 medication is ever appropriate in her case is a clinical question for her physicians, not a speculation topic.
The decision framework: should chronic-illness patients consider GLP-1 therapy?
For readers in a similar situation to Gomez (autoimmune disease, transplant history, or long-term corticosteroid use), the decision framework looks different from the standard one.
If you are managing corticosteroid-related weight gain:
- Discuss whether your steroid dose can be tapered or replaced with steroid-sparing agents
- Address weight as part of disease management with your rheumatologist or specialist, not as an independent cosmetic project
- If GLP-1 is considered, your specialist team should coordinate with the prescriber on interactions and monitoring
If you have an autoimmune condition and meet GLP-1 criteria:
- FDA criteria (BMI 30+, or BMI 27+ with comorbidities) still apply
- Your other medications, kidney function, and disease activity influence the timing and dosing strategy
- The reasonable starting point is conversation with your existing specialist team, not a separate weight-loss clinic
If you are a transplant recipient:
- Coordination with your transplant center is required, not optional
- Interactions with immunosuppressants need explicit review
- The single-kidney consideration affects both GLP-1 dosing and side-effect tolerance
If you are not the patient and you are watching a chronic-illness celebrity:
- The patient has more information than you do about her body
- Her stated explanations describe her treatment context
- Speculation has no positive function and reinforces a habit of demanding medical justification from visibly ill people
What public speculation does to chronic-illness patients
Gomez is unusual in how openly she has spoken about her disease. That openness has not protected her from speculation. The pattern is worth naming because it affects more people than her.
Speculation about chronic-illness patients produces three specific harms.
Harm 1: It treats medication as a moral category rather than a clinical one. The assumption that GLP-1 use is something to expose, hide, or speculate about presupposes a moral hierarchy of weight-loss methods. For chronic-illness patients, this framing collapses into hostility against anyone managing weight as a side effect of disease.
Harm 2: It assumes the patient is dishonest. Gomez has explained her body context for years. Continued speculation requires assuming she is lying about her treatment, which projects a strange moral suspicion onto a kidney-transplant recipient managing lupus.
Harm 3: It makes future disclosure harder. Patients with chronic illness face a calculation about whether to discuss their treatment publicly. When public discussion produces speculation rather than understanding, the rational response is silence. That hurts other patients who benefit from hearing their experiences described by someone visible.
The contrary view: could she be using something nobody knows about?
It is worth being honest about what we cannot rule out.
Argument 1: Patients with chronic illness sometimes take additional medications without disclosure.
Gomez is not obligated to disclose every medication. If she used a GLP-1 medication as part of her treatment regimen, she would be entitled to keep that private. The absence of disclosure is not proof of non-use.
Argument 2: Some autoimmune patients have found GLP-1 medications helpful for steroid-induced weight gain.
There is a small but growing clinical literature on using GLP-1 medications to address weight gain from glucocorticoid therapy. If Gomez’s care team explored this, it would fit her treatment context rather than contradict it.
Argument 3: Her appearance in 2024-2025 has shown some slimming.
Photos from her engagement period in late 2024 show a slimmer profile than during peak flare periods. This could reflect successful steroid tapering, a stable disease period, lifestyle changes during a happy life event, GLP-1 use, or any combination.
The counter:
None of these arguments produce evidence. Her public statements attribute her body changes to lupus medication. The corticosteroid pattern is the most parsimonious explanation for the cycling we have observed. If a GLP-1 medication were part of her chronic-illness management, the disclosure decision would belong to her and her team, not to speculation. The reasonable position is to take her at her word about lupus medication and stop asking the question.
FAQ
Is Selena Gomez on Ozempic? No credible evidence supports this claim. Gomez has explicitly attributed her weight fluctuations to her lupus medication, particularly corticosteroids, which produce water retention and weight gain on dosing cycles. She has addressed Ozempic speculation and rejected it.
What lupus medication does Selena Gomez take? She has not disclosed her full regimen. She has mentioned corticosteroids and treatment cycles. Common lupus treatments include hydroxychloroquine, prednisone, immunosuppressants, and post-transplant medications like tacrolimus. Each carries weight-related side effects.
Did Selena Gomez have a kidney transplant? Yes. In 2017, she received a kidney from her friend Francia Raisa. The transplant was a consequence of her lupus. Post-transplant immunosuppression is ongoing and affects weight.
What is moon face? A clinical sign of corticosteroid use. Facial fat and fluid redistribute, producing a rounded, puffy appearance, particularly in the cheeks and jaw. It resolves partially as steroid doses decrease.
What is Ozempic face? A description of facial volume loss from rapid weight reduction. It is not specific to GLP-1 medications; any significant weight loss can produce similar facial changes. It is visually opposite to moon face.
Why does Selena Gomez look different in different photos? Her body changes with her treatment cycle. Flare periods and high steroid doses produce visible weight gain and facial roundness. Stable periods produce a more typical appearance. Lighting, makeup, and ordinary year-to-year aging add to the variation.
Can people with lupus take GLP-1 medications? If they meet FDA criteria (BMI 30+, or BMI 27+ with comorbidities) and their care team supports the decision. Drug interactions with immunosuppressants, kidney considerations, and GI tolerance need explicit review. It is not a routine decision for autoimmune patients.
Is Selena Gomez on prednisone? She has discussed taking corticosteroids during flare periods, and prednisone is the most common one. She has not disclosed her current regimen in detail.
How did Selena Gomez lose weight in 2024? Her appearance in late 2024 showed some slimming, which could reflect a stable lupus period, lower steroid dosing, lifestyle changes during her engagement period, or other factors. She has not framed any 2024 change as Ozempic-related.
What did Francia Raisa say about Selena Gomez? Raisa donated her kidney to Gomez in 2017. The two have had a complicated public relationship since. None of the reported tension has involved GLP-1 medications.
Is Selena Gomez sick now? She manages chronic illness. Lupus is lifelong; treatment continues. Her disease activity varies, and her appearance reflects that. She has described herself as "doing well" in her current life despite the ongoing management.
Should I take Ozempic if I have lupus? Discuss with your rheumatology team and any specialists managing your case. The decision involves your weight-related FDA criteria, your medication regimen, your disease activity, and your tolerance profile. It is not a decision to make through a generic telehealth interface without coordination.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
- Rohrich RJ et al. Facial Volume Loss After Weight Loss: A Three-Dimensional Analysis. Plastic and Reconstructive Surgery. 2022.
- American College of Rheumatology. Guidelines for the Management of Systemic Lupus Erythematosus. 2023.
- KDIGO. Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. 2020.
- Endocrine Society. Clinical Practice Guideline: Treatment of Glucocorticoid-Induced Adverse Effects. 2022.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
- Pearl RL et al. Weight Bias and Stigma: Public Health Implications and Structural Solutions. Obesity. 2023.
- Davies MJ et al. Gastrointestinal Adverse Events with Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Care. 2023.
- American Society of Transplantation. Drug Interaction Considerations in Post-Transplant Care. 2024.
- Lupus Foundation of America. Lupus Treatment Guidelines and Patient Resources. 2024.
- FDA Drug Approvals Database. Semaglutide and Tirzepatide Indications and Labeling. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based 503A compounding pharmacies. FormBlends does not manufacture, prescribe, or dispense medication directly. All prescribing decisions belong to independent licensed clinicians.
Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide are not FDA-approved products. They are prepared by state-licensed 503A pharmacies in response to individual prescriptions. Compounded preparations have not been reviewed by the FDA for safety or efficacy and should not be considered equivalent to brand-name Ozempic, Wegovy, Mounjaro, or Zepbound.
Chronic Illness Notice. Patients with autoimmune disease, organ transplant history, or other complex medical conditions should coordinate any weight-management discussions with their existing specialist team. Information on this page is educational and does not substitute for clinical judgment in chronic-illness contexts.
Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Selena Gomez, Wondermind, Francia Raisa, or any company referenced on this page.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →